Initiation of antiresorptive drug treatment during endocrine therapy for breast cancer—A retrospective cohort study of 161,492 patients in Germany

Data from a retrospective cohort study of women with breast cancer who received endocrine therapy (tamoxifen or aromatase inhibitor [AI]) showed a higher cumulative incidence of antiresorptive drug prescriptions among patients treated with AI (14.5%) than those receiving tamoxifen (6.1%; p < 0.001). Patients receiving AI most frequently were prescribed denosumab while those treated with tamoxifen most often were administered alendronate.